Chief Medical Officer appointed at Aparito
Dr. Elin Haf Davies
Thu Sep 19 2019 00:30:00 GMT+0000 (Coordinated Universal Time)
Aparito is pleased to announce that Dr Anthony Hall MB, BS, BSc, AKC has been appointed to take on the role of Chief Medical Officer as of 24th July 2019.
Dr Anthony Hall (Tony) graduated from King’s College London with first class honours in physiology and pharmacology before going on to qualify as a doctor in 1991 from the Royal Free Hospital London. He joined the pharmaceutical industry in 1994 and has spent many years working on the development of drugs for rare diseases. Tony founded and developed the first orphan drug specialist Contact Research Organisation /consultancy, during which time he was involved in helping clients conceive innovative orphan drug development programmes. During the past 5 years Tony has worked at Prosensa and Biomarin on the development of antisense oligonucleotides for the treatment of Duchenne muscular dystrophy. As Therapeutic Area Head of Orphan Diseases at Mereo BioPharm, Tony also worked on the development of a monoclonal antibody for the treatment of osteogenesis imperfecta. Tony was one of the key people who conceived the development programme and clinical trials for the repurposing of nitisinone for the ultra-rare disease alkaptonuria (AKU). The DevelopAKUre Consortium, in which his company participated was awarded a EUR 6 million under the EU’s 7th Framework Programme and it is now anticipated that a Marketing Authorisation Application will be filed soon. Tony is Co-founder and Trustee of the rare diseases charity ‘Findacure’ and sits on the Scientific Advisory Board of the patient group Duchenne UK. He speaks regularly at rare diseases conferences and is author of a number of articles and book chapters on orphan drugs; together with the ‘Findacure’ Co-founder Nicolas Sireau, published a book entitled; “The Patient Group Handbook: A Practical Guide for Research and Drug Development”. CEO, Dr Elin Haf Davies said: I’m delighted that Tony has joined us. He brings in depth knowledge and understanding of developing medicines in rare disease, and a unique experience of having grown a company specialising in this area. We have no doubt that he will help us make great strides in the coming months across many different disease areas. Tony commented: “One of my major interests is how to streamline development programmes, whilst ensuring that clinical trials are designed in such a way as to capture data which is relevant for patients; something standard clinical endpoints cannot always do. I was therefore delighted to be asked to join Aparito as Chief Medical Officer in order to pursue this interest and help them to support clients drug development programmes for treatments that genuinely improve the quality of patients’ lives.”